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Over diagnosing? Time for the ‘exercise is medicine’ movement 
to react
Clinical medicine has been overdiagnosing for several 
years; sport and exercise medicine needs to guard 
against falling into the same trap. This was the message 
portrayed in a podcast in which Dr Karim Khan, editor 
of the British Journal of Sports Medicine, interviewed 
Ray Moynihan,[1] one of the authors of the bestselling book Selling 
Sickness: How the World’s Biggest Pharmaceutical Companies are 
Turning Us All Into Patients.[2] The concept of ‘selling sickness’ is 
becoming a major public health problem, with many patients being 
treated for diseases or injuries that do not require treatment. Often 
the treatment has more undesirable effects than no treatment at all. 
The driving force for overdiagnosing can have different origins. 
The most common origin can be attributed to profit, particularly if 
the condition needs medication, or expensive diagnostic procedures. 
Another driving force can be academic/clinical status; a clinician 
develops a reputation for being able to make an unusual diagnosis, 
and this behaviour seems to attract more unsuspecting patients. It 
does not take long for a condition to become fashionable. Consider, 
for example, the rather sudden increase in the number of patients 
getting diagnosed with conditions that used to be rare (chronic 
fatigue syndrome, irritable bowel syndrome, attention deficit 
hyperactivity disorder in children, to name a few). 
In the discipline of sport and exercise medicine, there are signs 
that overdiagnosing is becoming more mainstream. The number 
of referrals for a magnetic resonance imaging (MRI) diagnosis has 
increased precipitously. While it is accepted that elite professional 
sports participants need the best medical care to diagnose an injury, 
it is questionable whether a recreational athlete needs to incur the 
same expenses for a rather innocuous injury. While MRIs can identify 
structural abnormalities, these structural abnormalities may not be 
associated with pain or degeneration. There are many unanswered 
questions about the association between structural abnormalities, 
injury and degeneration. This raises the question of ‘what is normal?’ 
This is an important question, because the distinction between 
normality and abnormality forms the basis of medical practice. [3] 
According to this paradigm, if a condition is abnormal, it needs to 
be treated; if it is normal, it can be left alone. Differentiating between 
normal v. abnormal is not as simple as it may initially seem. For 
example, is it appropriate for age-associated conditions to be regarded 
as abnormal? Should 50-year-old men and women be prescribed 
hormone replacement therapy because they no longer have the same 
endocrine profile as someone in their twenties? For the definition 
of normal to be applied appropriately, gender- and age-based 
comparisons should be made; failure to do so opens opportunities 
for overdiagnosing. A caveat to this argument is that at some point, 
age-related changes are no longer considered normal. For example, 
the prevalence of sarcopenia and osteoarthritis increase with age and 
are regarded as a natural part of the ageing process. Therefore, one 
can argue that within a group of 80-year-olds, it is normal to have 
sarcopenia and osteoarthritis. But should they be regarded as normal 
and left untreated?[4] Or should they all be placed on medication to 
reduce these effects? If the definition of normal v. abnormal is precise 
and indisputable, the chances of overdiagnosing will diminish. A 
murky definition provides fertile ground for practitioners prone to 
overdiagnose. This area of indecision is where the pharmaceutical 
companies have taken the initiative and generated an industry 
providing a variety of medications to counter the consequences 
of ageing. It is an easy marketing exercise to prescribe a pill for a 
condition. Compare this with trying to encourage a person to become 
more physically active. Even in the presence of an overwhelming 
amount of evidence supporting the positive role of physical activity 
in treating and managing many of the conditions associated with 
increasing age, the task of getting people to become more physically 
active is daunting. It is going to take much marketing and canvassing 
to convince the public that there are alternative options to medication 
to counter the natural consequences of ageing. This message is 
encompassed in the vision of the ‘Exercise is Medicine’ movement.[5] 
They have a tough job ahead to make a case against overdiagnosing 
and treating ailments, particularly those conditions that occur as a 
consequence of getting old. 
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